Venclexta (Venetoclax) is the first FDA-approved treatment that targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is over-expressed in many patients with Chronic Lymphocytic Leukemia (CLL).

The patient must have been previously treated with at least one other approved treatment protocol without success. Venclexta (Venetoclax) may be the Holy Mary drug to try when everything else failed.

Patients on the Venclexta (Venetoclax) regime must be monitored as their can be severe side effects. During Human Trails a number of patients developed upper respiratory issues such as Pneumonia.

Patients also have to maintain a level of hydration – 1.5 to 2 liters per day. If averse symptoms arise then hydration may be have to be added intravenously.

I think the biggest issue to patients getting access to this drug, is that the reported cost of the drug is approx $100,000 US per year.

Speak with your Oncologist or other Cancer Secialist, about Venclexta (Venetoclax), if you have diagnosed with Chronic Lymphocytic Leukemia (CLL).

Click on this Link to Download the FDA Fact Sheets PDF for Venclexta (Venetoclax).

Click on this Link which details the FDA Approval of Venclexta (Venetoclax).

Click on this Link to visit the official Venclexta (Venetoclax) website.

Click on this Link to visit the Drugs.com website to read their detailed pages about Venclexta (Venetoclax).

Click on this line to visit the The Genentech^® Access to Care Foundation to see if you may qualify to get help the High Cost of being treated with Venclexta (Venetoclax). If you qualify, you may get Venclexta (Venetoclax) at no cost to you.

 

Posted by: Vincent Banial
http://www.uniquelytoronto.com

Disclaimer: Any Trademarks mentioned in this post are owned by the respective Trademark owner. There could be unintentional errors or omissions in this post. Always refer to the official sites to confirm details and any ongoing changes or updates. This post is subject to change without notice. Any offers mentioned in this post are also subject to change without notice.